ストックスクリーナーアプリを入手
4.53
5.89%
0.252
プレマーケット:
4.49
-0.04
-0.88%
前日終値:
$4.278
開ける：
$4.54
24時間の取引高:
5,086
Relative Volume:
0.39
時価総額：
$183.13M
収益：
-
当期純損益:
-
株価収益率:
-6.1708
EPS:
-0.7341
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+23.45%
1か月 パフォーマンス:
+34.67%
6か月 パフォーマンス:
-21.76%
1年 パフォーマンス:
+23.77%
1日の値動き範囲:
$4.53
$4.73
1週間の範囲:
$3.90
$4.73
52週間の値動き範囲:
$2.55
$6.4229
Genfit Adr Stock (GNFT) Company Profile
GNFT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
4.53 | 183.13M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | アップグレード | Stifel | Hold → Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Underperform |
| 2020-05-13 | ダウングレード | Kepler | Buy → Reduce |
| 2020-05-12 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-05-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | 繰り返されました | B. Riley FBR | Buy |
| 2019-06-25 | 開始されました | Stifel | Hold |
| 2019-04-24 | 開始されました | SVB Leerink | Outperform |
| 2019-04-22 | 開始されました | Barclays | Overweight |
すべてを表示
Genfit Adr (GNFT) 最新ニュース
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
GENFIT annonce les résultats préliminaires de l’Offre de Rachat proposée aux porteurs d’OCEANEs 2025 et la Convocation de l’assemblée générale des porteurs d’OCEANEs 2025 - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading - TradingView
GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
Genfit Adr (GNFT) 財務データ
Genfit Adr (GNFT) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):